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Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S244function is crucial to identify those at risk and institute pre-
emptive therapies. We hypothesize that T-cell receptor (TCR)
diversity after double umbilical cord blood transplantation
(dUCBT) will predict clinical outcomes.
Methods: 42 adult dUCBT recipients received ﬂudarabine,
melphalan, ATG with tacrolimus/sirolimus as GvHD pro-
phylaxis. TCRb CDR3 regions were ampliﬁed from unsorted
PBMCs and sequenced using the ImmunoSeq platform
(Adaptive Biotechnologies) at 3, 6 and 12 months after
dUCBT. Samples analyzed had predominantly donor T-cell
chimerism and no morphologic relapse. We analyzed 34
samples at 3 mos, 26 at 6 mos and 23 at 12 mos. Entropy/
Shannon’s diversity index and richness/Fisher’s alpha di-
versity were calculated from number and frequency of TCRb
sequences and normalized for sequencing depth. Higher
entropy and richness, measures of uncertainty and unseen
species within a complex population, reﬂect increased
diversity.
Results: Median age was 52 years (19-67). 57.1% were in
remission at dUCBT. Primary indications for dUCBT were
AML, NHL and MDS. Median follow-up among survivors was
47 months (18-91). 4-year OS was 41%; 4-year PFS was 26%.
As a whole, dUCBT recipients increased entropy and richness
of their T cell repertoire in the ﬁrst year. We categorized
subjects into 3 groups: relapse, NRM, or alive with neither
event. In the NRM cohort, median entropy and richness
values rose slightly from 3 to 6 mos then fell at 12 mos. In
comparison, median entropy and richness were higher in the
no event cohort between 3 and 12mos and rose substantially
to diversity levels found in healthy donors. (p¼0.01, 0.09,
0.004 for entropy at 3,6,12 mos; p¼0.06, 0.11, 0.006 for
richness at 3,6,12 mos). (Figure) Entropies of subjects who
relapsed did not differ from those of the no event cohort (not
depicted). In a similar analysis, entropy values for subjects
with chronic GvHD fell between 3 and 12 mos and were
signiﬁcantly lower than in subjects without any cGvHD,
relapse, or NRM at 12 mos (median entropy 5.9 vs 12.3,
p¼0.04). Inmultivariable analyses controlling for age, patient
sex, disease status, and diagnosis, high entropy was associ-
ated with lower NRM (HR 0.68, p<0.001), PFS (HR 0.79,
p¼0.009) and OS (HR 0.73, p¼0.005). High richness (log10
transformed) was associated with lower NRM (HR 0.3,
p<0.001) and OS (HR 0.30, p¼0.0003).
Conclusion: T-cell repertoire diversity as early as 3 months
after dUCBT is signiﬁcantly lower in subjects who eventuallyexperience NRM or cGvHD and does not expand with time
after transplant. These quantitative predictive indicesmay be
used to identify dUCBT recipients who merit more intensive
monitoring or prophylactic strategies against infection and
GvHD.377
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Background: Monitoring of cytomegalovirus (CMV) DNA by
PCR followed by preemptive treatment of CMV viremia
(CMVV) is an acceptable preventive strategy to reduce the
incidence of CMV tissue invasive disease (TID) after alloge-
neic hematopoietic cell transplant (HCT). Despite proactive
monitoring, some patients develop CMV TID leading to
adverse outcomes. We seek to characterize risk factors
associated with the development of CMV TID in HCT re-
cipients who were monitored and treated preemptively.
Methods: We reviewed the charts of 256 adult HCT re-
cipients, actively monitored for CMVV between January 1,
2009 and July 31, 2013. Our center preemptively monitors
allogeneic HCT recipients with weekly CMVDNA by PCR until
Day + 100, and thereafter every 2 weeks in patients with
GVHD. Antiviral therapy was initiated within 1 day of iden-
tifying signiﬁcant CMVV. Patients with CMV TID occurring
during preemptive monitoring were matched 1:1 by the
underlying disease, year of transplant, and time of follow-up
with controls that developed CMVV without TID.
Results: Of the 15 patients that developed CMV TID despite
preemptive therapy, 10 (66.7%) occurred within the ﬁrst 100
days following HCT. Median time from HCT to CMV TID was
62 days (range 25 -1137). All cases were gastrointestinal CMV
TID with 1 case of CMV-associated oral mucositis. 9/15 (60%)
had concurrent CMVV at the time of CMV TID diagnosis, and
4/15 (26%) were preemptively being treated with antivirals
for CMVV at the time of CMV TID diagnosis. The mean viral
load was 1,738.5 copies DNA/mL, range (0-9,699 copies DNA/
mL). 6/15 (40%) had at least one prior episode of CMVVwhich
had previously resolved. When compared with controls
there were no signiﬁcant differences in age, type of HCT, time
to CMV TID, conditioning therapy, donor matching, comor-
bidities, GVHD, level of initial CMVV, or CMV donor/recipient
serological status. No ganciclovir resistance was identiﬁed in
patients with CMV TID.
Conclusions: All cases of CMV TID were gastrointestinal
disease and tended to occur early after HCT. CMV TID
developed in the majority without preceding viremia. There
were no risk factors that could speciﬁcally identify patients
likely to develop CMV TID despite pre-emptive monitoring
and treatment. Gastrointestinal CMV TID remains an
inherent complication of a CMV preemptive strategy.378
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Our previous studies have shown the ability of human CD34+
cells to stimulate T cell alloproliferative responses in-vitro.
Here, we investigated the anti-CD34 T cell alloreactivity in-
vivo by co-transplanting human CD34+ cells and allogeneic T
cells of an incompatible individual into NSG mice. Human
CD34+ cells (2x105/animal) were transplanted with alloge-
neic T cells at different ratios ranging from 1:50 to 1:0.5, or
without as a control. Engraftment of human CD 45+ cells was
analyzed by ﬂow cytometry at 1, 2, 4, or 8 weeks. Marrow
engraftment of human CD45+cells was signiﬁcantly
decreased in mice transplanted at any CD34:T cell ratio
compared to control mice that did not receive T cells.
Transplantation of T cells resulted in graft failure since >98%
of human CD45+ cells in the marrow and spleen of NSG mice
were CD3+. A normal CD4:CD8 T cell ratio was detected and
CD4+ cells were mostly CD45RA+. Mice transplanted with
CD34+ and allogeneic T cells at 1:1 ratio were sacriﬁced at 1,
2, or 4 weeks to analyze the kinetics of human cell engraft-
ment in the bone marrow and spleen. At 2 weeks post
transplant, the bone marrow showed CD34-derived myeloid
cells, whereas the spleen showed only allo-T cells. At 4
weeks, all myeloid cells had been rejected and only T cells
were detected both in the bonemarrow and spleen. Based on
our previous in-vitro studies showing that T cell allor-
eactivity against CD34+ cells is mainly due to B7:CD28 cos-
timulatory activation, we injected the mice with CTLA4-Ig
(Abatacept, Bristol Myers Squibb) from d-1 to d+28 post
transplantation of CD34+ and allogeneic T cells. We found
that treatment of mice with CTLA4-Ig prevented rejection
and allowed CD34+ cells to fully engraft the marrow of NSG
mice at 4 weeks with an overall 13 + 7% engraftment of hu-
man CD45+ marrow cells (n¼5). These included 53 + 9%
myeloid CD33+ cells, 22 + 3% CD14+ monocytes, 7 + 2% CD1c
myeloid dendritic cells, and 4 + 1% CD34+ cells while CD 19 B
cells were only 3% and CD3+ T cells 0.5 + 1%. Persistent
myeloid engraftment was found at d+56 after stopping
CTLA4-Ig on d+28. Here we demonstrate that costimulatory
blockadewith CTLA4-Ig can prevent Tcell mediated rejection
of incompatible human CD34+ stem cells. We also show that
the NSGmodel can be utilized to test in-vivo immunotherapy
strategies aimed at engrafting human stem cells across HLA
barriers. These results will prompt the design of future
clinical trials of CD34+ cell transplantation for patients with
severe non-malignant disorders, such as sickle cell anemia,
thalassemia, immunodeﬁciencies or aplastic anemia.Figure 1. Overall Survival by HCT-CI Score379
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Introduction:We developed a 2 step approach to HI HSCT in
which a ﬁxed dose of allogeneic T cells are infused after
reduced intensity (RIC) or myeloablative conditioning (HSCT
step 1). After 2-3 days, cyclophosphamide (CY) 60 mg/kg/d x
2 is given to establish bidirectional tolerance. One day after
the CY, a CD 34 selected stem cell product is infused (HSCT
step 2). This approach has been associated with a lowincidence of non-relapse mortality (NRM) resulting in a
signiﬁcant improvement in overall survival (OS) in patients
(pts) undergoing HI HSCT at our institution. We used the
HCT-CI as one of several tools to establish an optimal
screening process for this new type of HSCT. Now with
substantial numbers of pts treated, we examined the pre-
dictability of this tool in pts undergoing the 2 step HI HSCT.
Methods: We retrospectively analyzed pts treated on the 2-
step HI protocols who had HCT-CI scores calculated for
screening purposes. Pts were divided into 3 previously
described risk groups: 0, 1-2, and  3. Survival data was
calculated according to Kaplan-Meier methods.
Results: We identiﬁed 157 pts; 61 female, 96 male, median
age 55 (range 19-78), 34% undergoing RIC HSCT with com-
plete HCT-CI data whowere transplanted from 2007 through
2013. As a whole, 23 pts (15%) had a HCT-CI score of 0, 55
(35%) had a score of 1-2, and 79 (50%) had a score of  3. A
HCT-CI score of 0 was associated with a signiﬁcantly
increased OS (p¼0.039) withmedian survival not reached for
HCT-CI score 0 or score 1-2 versus 21 months with score  3
(ﬁg. 1). We also examined the predictability of the HCT-CI on
OS of pts with (54%) versus without (46%) disease at HSCT,
and found that differences (ﬁgures 2-3) between HCT-CI
groups were limited to pts with disease at time of HSCT
(p¼0.003 vs p¼0.765). Twenty nine of 157 (19 %) died of
NRM: 3 pts (10%) in the 0, 8 (28%) in the 1-2, and 18 (62%) in
the  3 score groups respectively.
Conclusions: Analysis of HCT-CI as a screening tool in the 2
step HI HSCT suggests its ability to correctly identify pts in
the lowest score category as being at decreased risk for
mortality. Predictability of OS in pts with higher scores was
limited to those with disease at the time of HSCT. There was
also a suggestion that higher scores correlated with
increased rates of NRM. Of note, both the percent of pts with
3 points and their OS was higher in the 2 step group than
what was reported by Sorror in 2005. While we believe this
is due in part to the low NRM associated with the 2 step
method even in higher risk groups, we also note that more of
the 2 step pts had 2-3 points for low PFTs (80% vs 33%). This
indicates that the calculation of pulmonary function as
measured at our institution may have inﬂated the high risk
numbers, affecting optimal use of the tool. Next steps include
assessing PFT methodology as it affects the HCT-CI as well as
the utility of other comorbidity indices in conjunction with
the HCT-CI, including Karnofsky performance score.
